SHANGHAI and ROCHESTER, Minn., Oct. 8, 2018 /PRNewswire/ -- WuXi AppTec Group and Mayo Clinic recently received the 2018 MedTech Insight Award for the Best Partnership/Alliance on the formation of WuXi Diagnostics, the joint venture between the two parties. The award was received on September 26 in Philadelphia at the MedTech Conference, a premier annual gathering for the medical technology industry.
The In Vivo Award for Best MedTech Partnership/Alliance honors two or more organizations whose joint activity sets a new benchmark in health care. The partnership could involve multiple medical technology companies or pharmaceutical firms, or it could include a medical technology company and a contract research organization, research institute, not-for-profit, or cooperative group.
WuXi Diagnostics is a strategic collaboration between WuXi AppTec Group and Mayo Clinic. The joint venture is developing an open-technology platform, which enables every scientist to commercialize innovative ideas into cutting-edge clinical tests for complex diseases. The company will build up a medical databank based on its two enabling platforms and educate health care providers across all levels of hospitals. WuXi Diagnostics will accelerate the development of esoteric tests that both organizations will offer in their respective markets with the intent to benefit not only patients in China but around the world.
"We are pleased to receive this award. This joint venture is at a very early stage and is growing rapidly. Our vision is to ensure every disease can be precisely diagnosed," said Jason Liu, Ph.D., General Manager of WuXi Diagnostics. "With support from two great organizations -- WuXi AppTec Group and Mayo Clinic -- we are confident that WuXi Diagnostics will achieve its vision, enable doctors to make better diagnoses for their patients, elevate a hospital's disease-management program, and accelerate innovation for the clinical diagnostics industry. Together, we want to bring the best testing solutions from research to the clinical practice."
"Mayo Clinic is honored to receive this award from MedTech," said William Morice, II, M.D., Ph.D., President of Mayo Medical Laboratories and Chair of Laboratory Medicine and Pathology at Mayo Clinic. "WuXi AppTec Group has a deep understanding of the Chinese market, rich resources to support this joint venture, and the ability to execute. We are pleased to have this strong collaboration in China to accelerate diagnostic research into tests that will help patients all over the world."
About Mayo Medical Laboratories and the Department of Laboratory Medicine and Pathology
The Mayo Clinic Department of Laboratory Medicine and Pathology and its reference laboratory Mayo Medical Laboratories provide advanced laboratory testing and pathology services to support 4,000 health care organizations around the world. Revenue from this testing supports medical education and research at Mayo Clinic, a nonprofit worldwide leader in medical care, research and education for people from all walks of life. Complemented by collaborations with diagnostic and biotechnology companies, the department maintains a robust diagnostic test-development program, launching more than 100 new tests each year.
About Mayo Clinic
Mayo Clinic is a nonprofit organization committed to clinical practice, education, and research, providing expert, comprehensive care to everyone who needs healing. For more information, visit mayoclinic.org/about-mayo-clinic or newsnetwork.mayoclinic.org.
About WuXi Diagnostics
WuXi Diagnostics is a joint venture formed in 2018 between WuXi AppTec Group and Mayo Clinic. The company mission is to build an innovative platform which enables both esoteric testing service and in-vitro diagnostic (IVD) product innovation, integrates multi-dimensional data, generates clinical insights, benefits health of mankind through precision medicine, and ultimately fulfills the vision of "every disease can be precisely diagnosed."
About WuXi AppTec Group
WuXi AppTec Group is a leading global pharmaceutical, biopharmaceutical, and medical device open-access capability and technology platform with global operations. As an innovation-driven and customer-focused platform, WuXi AppTec Group provides a broad and integrated portfolio of services to help our worldwide customers and partners shorten the discovery and development time and lower the cost of drug and medical device R&D through cost-effective and efficient solutions. With its industry-leading capabilities such as small molecule R&D and manufacturing, cell therapy and gene therapy R&D and manufacturing, medical device testing, biologics R&D and manufacturing, genomics and molecular diagnostics, WuXi platform is enabling more than 3,000 innovative collaborators from more than 30 countries to bring innovative healthcare products to patients, and to fulfill WuXi's dream that "every drug can be made and every disease can be treated."
